South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol

PHASE4RecruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

September 27, 2027

Study Completion Date

September 27, 2030

Conditions
Arsenic TrioxideChildhood ALL
Interventions
DRUG

Realgar Indigo naturalis formula

Realgar Indigo naturalis formula was used in the induction, consolidation and intensive treatment of patients in intermediate or high risk

COMBINATION_PRODUCT

Conventional chemotherapy

conventional chemotherapy

Trial Locations (1)

510120

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Zhujiang Hospital

OTHER

collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Guangzhou First People's Hospital

OTHER

collaborator

Huizhou Municipal Central Hospital

OTHER

collaborator

First Affiliated Hospital of Shantou University Medical College

OTHER

collaborator

Zhongshan People's Hospital, Guangdong, China

OTHER

collaborator

Zhongshan Bo Ai Hospital

OTHER

collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

collaborator

LiuZhou People's Hospital

OTHER

collaborator

Second Xiangya Hospital of Central South University

OTHER

collaborator

Hainan People's Hospital

OTHER

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT05682131 - South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol | Biotech Hunter | Biotech Hunter